North Estonia Medical Centre Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2015
NCT02596243
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

North Estonia Medical Centre

Active Ingredients

Drugs in Phase 2 Trials (1)

gx-188e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma in Situ (Phase 2)

Cervical Intraepithelial Neoplasia (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1